Examining Racial Differences in Utilization of Genetic Counseling Services in Hereditary Cancer Network Database

Similar documents
APPLYING AN IMPLEMENTATION SCIENCE APPROACH TO GENOMIC MEDICINE: A WORKSHOP

CDC Programmatic Activities in Breast and Ovarian Cancer Genomics

Lynch Syndrome: A Public Health Approach

Genomic/Genetic Services: Barriers to Access. Sue Friedman, DVM National Academies of Science Roundtable 06/26/18

ASTHMA BY RACE AND ETHNICITY

Reference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

So, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.

SURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases

Does Cancer Run in Your Family?

Sporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES

Genetic Screening Visit

Genetic Determinants, Risk Assessment and Management

Does Cancer Run in Your Family?

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.

BRCA Precertification Information Request Form

BRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview

Clinical Quality Assurance Measures at Myriad Genetic Laboratories:

WELCOME. Taking Care of Your Health. April 30, 8 am to noon

HBOC. Jessica M. Salamone, ScM, CGC

Importance of Family History in Gynecologic Cancer Prevention. Objectives. Genetic Counselors. Angela Thompson, MS, CGC

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

Assessing the Status of BRCA Testing and the Challenges Faced by Cancer Care Teams in the Community


Lansing, Michigan. Assignment Description

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

GeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information

RHODE ISLAND CANCER PREVENTION AND CONTROL

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women

BRCA1 and BRCA2. patient guide. genetic testing for hereditary breast and ovarian cancer (hboc)

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

Risk Assessment, Genetics, and Prevention

HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.

Genetic Testing: who, what, why?

GENETIC TESTING FOR HEREDITARY CANCER

PROVIDER POLICIES & PROCEDURES

Advice about familial aspects of breast cancer and epithelial ovarian cancer

Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer

Hereditary Aspects of Pancreatic Cancer

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2

Why Test for Hereditary Cancer in Preventive Care?

Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center

A guide to genetic testing for hereditary cancers

We know that treatments are now targeting genes, but does genetics play a bigger role in cancer outside of that?

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Genetic testing for hereditary cancer. An overview for healthcare providers

Thyroid cancer in the United States: Recent increases

WHAT DO GENES HAVE TO DO WITH IT? Breast Cancer Risk Assessment and Risk Reduction in 2016

GENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS

Florida Breast Cancers: Genetic Testing and Counseling

La Follette School of Public Affairs

Management of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH

American Cancer Society Progress Report. December 2016

Descriptive Statistics and Trends for Michigan Community Health Centers Region 4

Applies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans

Assessing the Status of BRCA Testing and the Challenges Faced by Cancer Care Teams in the Community. Summary of Survey Findings April 2018

PRINCIPLES FOR ELIMINATING DISPARITIES THROUGH HEALTH CARE REFORM. John Z. Ayanian, MD, MPP

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Universal BRCA1 and BRCA2 Genetic Testing for Ovarian Cancer Patients

CLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014

Disparities in Transplantation Caution: Life is not fair.

THE STATE OF ASTHMA IN INDIANA

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina

Enrollment under the Medicaid Expansion and Health Insurance Exchanges. A Focus on Those with Behavioral Health Conditions in Michigan

BRCAnowTM It s Your Decision

AllinaHealthSystems 1

Medical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011

Will Equity Be Achieved Through Health Care Reform?

Genetic Testing for BRCA1 and BRCA2 Genes

Community Benefit Strategic Implementation Plan. Better together.

The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice

Overview from the Division of Cancer Prevention and Control

11/29/2017. Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR. Genetics 101. Transcription vs Translation

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

A Patient s Guide to. Hereditary Ovarian Cancer: Is Hereditary Cancer Testing Right for You?

Cancer Genomics 101. BCCCP 2015 Annual Meeting

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

TumorNext-HR D. patient guide. a test for ovarian cancer patients to identify hereditary and tumor-specific mutations

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

2017 Breast Cancer Update

Day-to-Day Activities The Fellow will have opportunities to:

Hereditary Cancer Products

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

Genetic Risk Assessment for Cancer

Understanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious

PMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table

Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?

2016 Community Service Plan & Community Health Improvement Plan

Increasing Clinical Trials Enrollment: Resources

Ethnic disparities in melanoma diagnosis and survival

Re: NC Medicaid and NC Health Choice Program coverage of genetic testing for susceptibility to breast and ovarian cancer

SHARSHERET. New Recommendations for Genetic Testing: How Do I Make Sense Of It All?

30 TPHA Journal Volume 65, Issue 2

INCREASING REPRESENTATION IN A MIXED-MODE QUALITY OF LIFE SURVEY OF MEDICARE ESRD BENEFICIARIES

Transcription:

Examining Racial Differences in Utilization of Genetic Counseling Services in Hereditary Cancer Network Database Taylor Seaton, MS Cancer Genomics Epidemiologist MDHHS Cancer Genomics Program: Lifecourse Epidemiology and Genomics Division November 2017

Background: Genetic Cancer Hereditary Breast and Ovarian Cancer (HBOC) Breast cancer risk: 46% - 71% in women and 2.8% in men Ovarian cancer risk: 17% - 46% Lynch Syndrome Colorectal cancer risk: 22% - 92% Endometrial cancer risk: 20% - 70% Ovarian cancer risk: 4% - 12% 2

Background: National Comprehensive Cancer Network Guidelines 2.2017: BRCA ½ Testing Criteria Meeting one or more of these criteria warrants further assessment and genetic testing and management Known Familial Mutation Ashkenazi Jewish Personal HX of Breast Cancer diagnosed at age 50 or younger Personal HX of Multiple Primary Breast Cancer Personal HX of Male Breast Cancer Personal HX of Triple Negative Cancer Personal HX of Ovarian, Prostate, or Pancreatic Cancer No personal HX but a significant family history National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. BRCA ½ Testing Criteria Version 2.2017. Accessed August 2017. http://www.nccn.org/index.asp. 3

Michigan Cancer Surveillance Program: 15-Yr Annual Age-Adjusted Incidence Rates for Breast Cancer- Age 50 or Younger, by Race 60.0 Age-Adjusted Incidence Rate (per 100,000) 50.0 40.0 30.0 20.0 10.0 0.0 White Black Year Statistics provided by the Michigan Cancer Surveillance Program, September 2017 4

Michigan Cancer Surveillance Program: 15-Yr Annual Age-Adjusted Mortality Rates for Breast Cancer- Age 50 or Younger, by Race 14.0 Age-Adjusted Mortality Rate (per 100,000) 12.0 10.0 8.0 6.0 4.0 2.0 0.0 Black White Year Statistics provided by the Michigan Cancer Surveillance Program, October 2016 5

Background: Recent Studies on Racial Disparities and Genetic Testing Black women less likely to receive a physician recommendation for BRCA ½ testing 1 Difference remained after adjusting for mutation risk Black women diagnosed with breast cancer are less likely to receive genetic testing compared to White women 2 Predictors of BRCA ½ testing uptake include being at high risk of mutation, understanding the benefits of testing, and having few financial and administrative barriers Rates of risk reducing surgeries are lower among Black BRCA carriers compared to White and Hispanic carriers 3 Also found discussion of genetic testing with a provider was 16 times less likely among Black women compared to White women. 6

DP-14-1407: Promoting System Change Through Education, Surveillance, and Policy to Advance Cancer Genomics Best Practices 5 year CDC Cooperative Agreement Long-term aim: to reduce mortality rates of hereditary cancers by overcoming barriers and advancing health system changes to promote cancer genomics best practices Surveillance Strategy: To develop and expand surveillance systems on hereditary cancers and use of cancer genomics best practices for Hereditary Breast and Ovarian Cancers (HBOC) and Lynch Syndrome (LS) 7

BRCA Database and Hereditary Cancer Network Database, 2008-2015 Clinical data collected on all HBOC/BRCA-related genetic counseling visits conducted by board-certified/ eligible genetic specialist at 18 clinic locations across Michigan Starting in 2015, case definition increased to include LS-related visits Adults, age 18 or older Patient visits from 2008-Present Data includes: Demographics, visit information, personal and family history of cancer, BRCA testing results, and cancer-related surgical procedures Current analysis examines patients who self-identified as either White or Black for years 2008-2015 Total Population = 20,275 (N=1,859 under new case definition) White Population= 16,569 (81.7%) Black Population= 1,502 (7.4%) Other Population= 2,204 (10.9%) 8

Racial Distribution: MI Overall Population vs Hereditary Cancer Network Database Patients Counseled Black 14% Other 9% Black 7% Other 11% 1 1 MIPopulation 2010 White 77% White 82% Hereditary Cancer Network Database 2008-2015 MI Population Data Source: US Census QuickFacts, 2015 1 Other = Asian, American Indian/Alaska Native, Native Hawaiian/PI, Hispanic, Multi-racial 9

Initial Genetic Counseling Visits by Race: 2008-2015 3000 2500 Patients Counseled in the Hereditary Cancer Network Database by Race 2774 2637 2633 2385 2103 2000 # of Patients 1500 1091 1338 1608 White Black 1000 500 92 140 133 207 232 221 215 262 0 2008 2009 2010 2011 2012 2013 2014 2015 Due to methodology changes that took place in 2014, estimates from 2014 and moving forward cannot be compared to estimates from 2013 and earlier 10

Characteristics of Patients in Hereditary Cancer Network Database by Race: 2008-2015 Average Age Black: 49.3 years (Range 18 to 83) White: 51.9 years (Range 18 to 94) 11

Characteristics of Patients in Hereditary Cancer Network Database by Race: 2008-2015 Insurance Status Medicaid 1 Medicare Private 1 Uninsured Unknown Black (N=1,502) 187 (12%) 181 (12%) 997 (66%) 17 (1%) 120 (9%) White (N=16,569) 568 (3%) 2,567 (15%) 11,789 (71%) 142 (1%) 1,503 (10%) 1 Statistically Significant at P value < 0.05 Referring Provider Black (N=1,502) White (N=16,569) Internal Med 1 Oncologist 1 OB/GYN Self 1 Surgery Other 1 Missing data Black N= 53 (4%), White N=1,396 (9%) 1 Statistically Significant at P value < 0.05 142 (9%) 455 (30%) 203 (14%) 50 (3%) 357 (24%) 242 (16%) 1,069 (6%) 3,214 (19%) 2,323 (14%) 1,474 (9%) 3,984 (24%) 1,474 (19%) 12

Counseled, Tested, and Received Positive Result by Race: 2008-2015 White Black 18,000 16,552 1,600 1,501 16,000 1,400 14,000 1,200 12,000 10,000 8,000 10,274, (62%) 1,000 800 783, (52%) 6,000 600 4,000 2,000 1,328, (13%) 400 200 67, (9%) 0 0 Initial Visit Genetic Testing Ordered At Least 1 Positive Result Initial Visit Genetic Testing Ordered At Lest 1 Positive Result 13

Genetic Test Type by Race: 2008-2015 Black N=710 White N=9,178 Site Specific, 5% Ashkenazi, 0% BART, 7% Ashkenzi, 7% BART, 8% Site Specific, 16% Comprehensive, 89% Comprehensive, 69% All comparisons statistically significant at p-value <0.05 14

Reasons Why Genetic Testing was not Pursued by Race Black N=719 White N=6,280 Unkown 46% Insurance Coverage 16% 2 Chose not to Test 8% Insurance 2 Coverage 11% Chose not to Test 8% Not a good Candidate Unkown 50% Not a good Candidate 20% Other 8% 1,2 22% Other 11% 1,2 1 Other includes: Patient previously tested, waiting to talk to relatives, concern about genetic discrimination, wants to test elsewhere. 2 Statistically significant at p-value <0.05 15

Initial Genetic Counseling Visits and Testing by Race and Gender Initial Counseling Visits Black N (%) White N (%) Total N(%) Female 1,449 (97%) 15,487 (94%) 16,936 (94%) Male 52 (3%) 1,065 (6%) 1,117 (6%) Total 1,501 (100%) 16,552 (100%) 18,053 (100%) Genetic Testing Ordered following Initial Visit Black N (%) White N (%) Total N(%) Female 753 (52%) 9,566 (62%) 10,319 (61%) Male 29 (56%) 696 (65%) 725 (65%) Total 782 (52%) 10,262 (62%) 11,044 (61%) 16

Genetic Counseling in Males by Race Age Adjusted Breast Cancer Incidence Rates for 2008-2013 in Males 1,2 Black: 2.64 / per 100,000 White: 1.36/ per 100,000 Personal Cancer History Any Cancer 2 BRCA Related Cancer 2,3 Breast Cancer 2 Black 35 (67%) 25 (48%) 18 (35%) White 518 (49%) 274 (26%) 127 (15%) Family Cancer History Known Familial Mutation 2 No Personal HX, Familial BRCA Related Cancer 2-4 Black 4 (8%) 20 (38%) White 358 (34%) 686 (65%) 1 Statistics provided by the Michigan Cancer Surveillance Program, September 2017 2 Statistically significant at p-value < 0.05 3 BRCA Related Cancer defined as Breast, Ovarian, Prostate or Pancreatic Cancer 4 Abbreviation: HX=history 17

Select NCCN Guideline Criteria among Counseled Patients by Race: 2008-2015 45% 43% 40% 37% 35% 30% 25% 25% 25% 23% 20% 15% 12% 16% 18% 15% 13% 10% 5% 0% 3% Known Familial 1 Mutation 1 BC at 45 3% 2% BC Multiple Primaries BC at 50 & Family HX of 1 BC 7% BC at 50 & No 1 Family HX BC & Significant 1 Family HX 3% 0% BC & Ashkanazi 1 Jew 5% 2% 1% 1% 1 OC Male BC No Personal HX, Familial 1,2 BRCA Cancer White Black Abbreviations: BC= Breast Cancer OC=Ovarian Cancer 1 Statistically significant at P-Value < 0.05 2 BRCA Related Cancer defined as Breast, Ovarian, Prostate, and Pancreatic Cancer 18

Summary of Major Findings Blacks are underrepresented in this genetic counseling database Statistically significant differences exist in genetic testing by race Insurance coverage a barrier? Blacks were more likely to be younger and with a personal history of cancer Whites were more likely to have a known familial mutation or significant family history without having a personal history of cancer Cascade Screening important to identify those without personal history 19

Limitations Not representative of all Genetic Counseling 18 clinics represented Varying time frame for each clinic Counties with At least 1 Genetic Counseling Clinic Represented in Clinical Database Only includes genetic tests ordered by a genetic counselor Does not account for Direct to Consumer testing Only started collecting data on triple negative breast cancer in 2015 20

Current and Future MDHHS Projects for Genetic Counseling and Testing Biannual updates with Clinical Partners Provide genetic clinics reports of their patient population regularly Analyze data for Lynch Syndrome Conduct workshops with Michigan Association of Health Plans (MAHP) To provide resources and answer questions on testing, guidelines, policy, informed consent Cascade Screening Call to Action Meeting on Sept. 29th Increase Public Awareness Ad campaign Hereditary Colorectal Cancer Family Day on Nov 11 th (Partnered with U of M) 21

MDHHS Clinical Network Participants Beaumont Cancer Genetics Program Beaumont Hospital-Dearborn Genetic Risk Assessment for Cancer Clinic Henry Ford Health System Cancer Genetics Program Karmanos Cancer Institute Cancer Genetic Counseling Service InformedDNA Telephone Genetic Counseling Services Mid-Michigan Hereditary Cancer Clinic Michigan State University Hereditary Cancer Program Marquette General Hematology/Oncology St. Joseph Mercy Hospital Cancer Genetics Program St. John Providence Health System Cancer Genetics Program (Southfield and Grosse Pointe Woods, MI) St. Mary Health Care Lacks Cancer Center Genetics (Grand Rapids, MI) St. Mary Mercy Our Lady of Hope Cancer Center (Livonia, MI) University of Michigan Breast and Ovarian Cancer Risk and Evaluation Program University of Michigan Cancer Genetics Clinic West Michigan Cancer Center Munson Cancer Genetics Clinic Spectrum Health Cancer Genetics Program 22

References 1. McCarthy et al. Health Care Segregation, Physician Recommendation and Racial Disparities in BRCA ½ Testing among Women with Breast Cancer. J Clin Oncol. 2016: 34;2610-2618 2. Jones et al, Predictors of BRCA1/2 testing among Black women with breast cancer: Population-based study. Cancer Medicine 2017, 6(7):1787-1798. 3. Cragun et al., Racial Disparities in BRCA Testing and Cancer Risk Management Across a Population-Based Sample of Young Breast Cancer Survivors. Cancer 2017, 123:2497-505 23

Disclaimer Funding for this project was made possible in part by the Centers for Disease Control and Prevention. The views expressed herein do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government 24

THANK YOU! Please contact Taylor Seaton at (517)373-2929/ seatont1@michigan.gov for further questions or comments 25